Isothermal Amplification Market Size is expected to witness appreciable growth between 2022 and 2028. This can be credited to the low power consumption and compatibility of isothermal amplification techniques with hand-held equipment, due to the non-requirement of thermal cycling. In addition, the rising prevalence of transfusion-transmissible infections will augment the industry expansion, on account of the significant usage of loop-mediated isothermal amplification (LAMP) in detecting pathogens in blood samples. Isothermal amplification refers to the continuous and exponential amplification of the nucleic acid sequences using enzymes, typically strand displacing polymerases, at a constant temperature. This technique usually adopts DNA polymerases and specially designed primer sets to amplify the target sequence.
Rapid advances in viral pathogen detection techniques and escalating infectious disease outbreaks are the major factors stimulating market trends through 2028. For example, researchers at KIMS, a research institute in South Korea, have developed a plasmonic isothermal RPA (recombinase polymerase amplification) array chip, which can detect pathogens that cause acute respiratory diseases in just 30 minutes. Moreover, the advancement of molecular diagnostics technologies, including INAAT (isothermal nucleic acid amplification technology), for detecting infectious and non-communicable diseases will propel the industry share during the forecast timeline.
Blood screening is likely to emerge as a prominent application segment for the isothermal amplification market by 2028. Growth from the segment is attributed to the lack of timely access to safe blood and the consequent increase in number of blood donors in high-income regions. According to the WHO, out of the total 118.5 million blood donations globally, 40% are collected in high-income countries. This factor could boost the adoption of isothermal amplification methods to detect the presence of viruses and other pathogens in blood.
The Asia Pacific isothermal amplification market will depict a strong growth rate through 2028, driven by the growing incidences of cancer in the region. Given the increasing evaluation of RT-LAMP assay for detecting tumor involvement of lymph nodes in breast cancer patients, the surging disease prevalence in nations like Korea could add impetus to the regional outlook. Furthermore, the expansion of specialty hospitals, including for cancer and tertiary level care, will also impel the deployment of the technique across the region.
Some of the major companies operating in the global isothermal amplification market include Ustar Biotechnologies, Quidel Corporation, Qiagen, OptiGene, Meridian Bioscience, Lucigen (LGC Ltd.), Hologic (formerly Gen-Probe), Eiken Chemical, bioMerieux SA (Institut Mérieux, Sofina), Abbott (formerly Alere), Thermo Fisher Scientific, and Becton, Dickinson and Company. These industry participants are introducing new products and entering mergers and acquisition deals to reinforce their presence across the global market. For example, in June 2021, Meridian Bioscience, Inc. unveiled its Lyo-Ready™ RT-LAMP Mix, designed specifically for the robust, rapid, and sensitive detection of RNA viruses.
The unprecedented impact of the coronavirus outbreak has been showcased across the healthcare sector, owing to the implementation of lockdown as well as economic and social crises. The pandemic has also threatened to reverse the gains made by the Global Fund partnership in its fight against malaria, TB, HIV, and other infectious diseases due to its disruptions to health services. These aforesaid factors have adversely affected the business landscape worldwide.
However, the increasing reliance on varied molecular diagnostic techniques to detect COVID-19 may aid industry recovery. In December 2020, for instance, Quidel Corporation gained an EUA from the U.S. FDA for its Solana SARS-CoV-2 Assay, an isothermal RT-HDA (Reverse Transcriptase - Helicase-Dependent Amplification) assay. This use of this assay was intended for the detection of nucleic acid from SARS-CoV-2 present in nasal and nasopharyngeal swab specimens, thus presenting growth opportunities for the industry during the forecast timeframe.
Market, By Product
Market, By Application
Market, By End-use
The above information is provided for the following regions and countries: